---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-25-000198"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:36:23.949624+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Emergent Q3 revenue $231.1M beats guidance; raises FY2025 revenue & EBITDA view

## Summary
- Total revenue $231.1M (above Q3 guidance high by $21M); net income $51.2M ($0.91 EPS).
- Adjusted EBITDA $87.8M (38% margin); adjusted EPS $1.06; gross margin expanded 300bps to 54%.
- Naloxone segment down 21% to $74.9M; MCM down 18% to $142.5M; Other Products up 91% to $57.5M.
- FY2025 guidance raised: revenue $775-$835M (from $765-$835M), adjusted EBITDA $195-$210M (from $175-$200M).
- Secured $56M ACAM2000, $52M CNJ-016, $30M CYFENDUS, $29M international MCM contracts in Q3.

## SEC filing metadata
- accession: 0001367644-25-000198
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000198/0001367644-25-000198-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000198/ebs-20251029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-25-000198
- JSON: https://secwatch.observer/filing/0001367644-25-000198.json
- Plain text: https://secwatch.observer/filing/0001367644-25-000198.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.